Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Immatics US Inc. launches in Houston
October 2015
SHARING OPTIONS:

TUEBINGEN, Germany—Immatics Biotechnologies GmbH and The University of Texas MD Anderson Cancer Center in Houston have opened the doors to Immatics US Inc., a new company focused on becoming a global leader in adoptive cellular therapies (ACT) for the treatment of a variety of cancers. Immatics US has secured a first funding round of more than $60 million, with more than $40 million committed by Immatics Biotechnologies and $19.7 million by a recent grant from the Cancer Prevention and Research Institute of Texas. The new company will be advancing three different ACT approaches for treating tumors with high unmet medical needs, with the first of those expected to enter the clinic next year.
 
“Our ongoing efforts to provide the most innovative therapies to our patients are due, in part, to collaborations both in academia and industry,” said Dr. Ronald DePinho, president of MD Anderson. “It is only through working with other leaders in cancer science will we provide the solutions of tomorrow.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.